Selection from HEOR Bibliography
| Search criteria | ||||
| Czech |
||||
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries | ||||
| Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi | ||||
| IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK | ||||
| Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA. |
||||
| , Poster | ||||
| , Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland | ||||
| Abstract: https://www.coodoc.com/pages/p1822-Daratumumab-ICPE-2019 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology, Oncology | 2019 | English | , Public Health, Survey research | |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. | ||||
| Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 | ||||
| 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium | ||||
| ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
| , Oral presentation | ||||
| , Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES | ||||
| M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. DÃaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group | ||||
| 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway | ||||
| EULAR, Madrid, 2017 |
||||
| , Abstract | ||||
| , Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland | ||||
| Abstract: http://ard.bmj.com/content/76/Suppl_2/656.3 | ||||
| Condition | Year | Language | Analysis type | |
| , Rheumatology | 2017 | English | , Epidemiological study | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| Rationale and design of a multi-center survey to evaluate productivity losses and indirect costs after cardiovascular events in Europe. | ||||
| Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Annemans L3 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Amgen (Europe) GmbH, Zug, Switzerland 3 University of Ghent, Ghent, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium, Czech, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Switzerland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2016 | English | ||
| Survey on appropriateness of use of nimesulide in nine European countries | ||||
| Franchi S1, Heiman F2, Visentin E2, Sacerdote P1. | ||||
| 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. 2Cegedim Strategic Data Medical Research Srl, Milan, Italy. | ||||
| Drug, Healthcare and Patient Safety 2015:7 51-55 |
||||
| , Article | ||||
| , Bulgaria, Czech, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia | ||||
| Condition | Year | Language | Analysis type | |
| , Pain | 2015 | English | , Survey research | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Czech Republic | ||||
| Troelsgaard A1, Pitcher A2, Veselá Š3, Lovato E2, Hemels M1 | ||||
| Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Janssen-Cilag Czech Republic, Prague, Czech Republic | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Czech | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Long-term clinical and cost outcomes of treatment with insulin detemir plus insulin aspart in type 1 diabetes patients in the Czech setting; data from the predictive study | ||||
| 1Clegg JP, 1Valentine WJ, 2Rychna K, 3Honka M, 4Doležal T | ||||
| 1IMS, Allschwil, Switzerland, 2Novo Nordisk s.r.o, Praha 6, Czech Republic, 3Faculty Hospital Ostrava, Ostrava, Czech Republic, 4Charles University in Prague, Prague 10, Czech Republic | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Czech | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |